Best Startup
At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United States based Chairman operating in the Biotechnology space. If you think a Chairman is missing from this list, feel free to contact our editor on editor@beststartup.us.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Jonathan Milner
Chairman & Co-founder of Axol Bioscience
Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon Discovery Group plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.
Follow Jonathan Milner:
About Abcam, Axol Bioscience, Milner Centre for Evolution, Natural History Museum, SyndicateRoom: Axol Bioscience sells live human cell cultures and provides services such as genome editing to researchers.
Paul Bisaro
Executive Chairman of Allergan
Paul Bisaro currently serves as Executive Chairman of Allergan and the Company’s Board of Directors. He served as the Chief Executive Officer of Actavis from September 2007 to July 2014. Prior to joining Actavis (then Watson), he was President and Chief Operating Officer of Barr Pharmaceuticals, Inc. (“Barr”) from 1999 to 2007. Between 1992 and 1999, Mr. Bisaro served as General Counsel and from 1997 to 1999 served in various additional capacities including Senior Vice President — Strategic Business Development at Barr. Prior to joining Barr, he was associated with the law firm Winston & Strawn and a predecessor firm, Bishop, Cook, Purcell and Reynolds from 1989 to 1992. He also served as a Senior Consultant with Arthur Andersen & Co. Mr. Bisaro received his undergraduate degree in General Studies from the University of Michigan in 1983 and a Juris Doctor from Catholic University of America in Washington, D.C. in 1989.
Follow Paul Bisaro:
About Allergan: Allergan is a global pharmaceutical company.
Brenton Saunders
Chairman, President and Chief Executive Officer of Allergan
Brent Saunders is Chief Executive Officer and President of Allergan plc (formerly Actavis plc). Brenton previously served as Chief Executive Officer and President of Forest Laboratories and had served as a Member of the Board of Directors at Forest since 2011. Brenton has significant healthcare industry expertise and a proven track-record leading business transformations and integrations. Prior to Forest, Brenton was Chief Executive Officer of Bausch + Lomb, a leading global eye health company, serving in this capacity from March 2010 until August 2013. Brenton also held a number of leadership positions at Schering-Plough, including the position of president of Global Consumer Health Care and was named head of integration for the company’s merger with Merck & Co. and for Schering-Plough’s acquisition of Organon BioSciences. Before joining Schering-Plough, Brenton was a Partner and Head of Compliance Business Advisory at PricewaterhouseCoopers LLP. Prior to that, Brenton was Chief Risk Officer at Coventry Health Care and Senior Vice President, Compliance, Legal and Regulatory at Home Care Corporation of America. Brenton began his career as Chief Compliance Officer for the Thomas Jefferson University Health System. Brenton serves on the Board of Trustees of the University of Pittsburgh. Brenton is also the former Chairman of the New York chapter of the American Heart Association. Brenton is a Member of the Business Council and PhRMA. Brenton earned his MBA from Temple University School of Business, his J.D. from Temple University School of Law and his Bachelor’s degree from the University of Pittsburgh.
Follow Brenton Saunders:
About Allergan, Cisco: Allergan is a global pharmaceutical company.
Sam Santhosh
Founder Chairman & Global CEO of MedGenome
Sam Santhosh is the Founder and CEO of MedGenome. He has been an entrepreneur, with over 20 years of experience in the software industry. Currently, he is at the helm of affairs as CEO and promoter of MedGenome Labs Pvt Ltd. Sam sits on the board of a number of companies, both in the US and India. In this role he advises, guides and mentors companies to help them grow and realize their true potential. Prior to this Sam was the CEO and Managing Director of California Software Limited (Calsoft) from 1992 – Feb 2012. He founded Calsoft in 1992 and under Sam’s vision, Calsoft rapidly grew from a niche player in the Silicon Valley to a global player with over 1200 employees and presence in 8 countries. Sam took Calsoft Public and the company is listed the in Indian Stock Exchanges. Sam oversaw the growth of Calsoft in all key areas – Finance, Strategy, Customer Acquisition, and inorganic growth through eight acquisitions including companies in the U.S, UK, Japan, and India. He has been constantly retooling himself and has attended various training programs in different U.S universities including MIT. In 2010, he completed the Executive Education program at the Singularity University in Sunnyvale, California. Sam has an engineering degree and an MBA (majoring in Management Information Systems) from India’s premier institute, IIM Calcutta.
Follow Sam Santhosh:
About Agrigenome, MedGenome: MedGenome develops a genomics-based diagnostics and research solution for healthcare providers to understand the genetic basis of diseases.
Jeff Aronin
Chairman and Co-founder of Evozyne
Jeffrey S. Aronin has decades of experience developing innovative global biotech and health care companies. His keen ability to identify ideas and scientific innovations with the highest potential to change lives and improve the world has made Mr. Aronin one of the most impactful and successful leaders in the life science sector. As an entrepreneur and scientific visionary, with a focus on addressing unmet patient and societal needs, Mr. Aronin has received U.S. Food and Drug Administration (FDA) approval of numerous new medicines and technologies. His companies are renowned for advancing science, with a record number of breakthroughs helping patients, and economic engines, having created thousands of job opportunities throughout the world. As founder of Paragon Biosciences, Mr. Aronin serves as its chairman and chief executive officer. Paragon is a life science innovator that creates, invests in, and builds bioscience companies in biotechnology, gene therapy and synthetic biology. Paragon Biosciences founded Castle Creek Biosciences, CiRC Biosciences, Emalex Biosciences, Evozyne, Harmony Biosciences, Qlarity Imaging, and Skyline Biosciences, and maintains a consistent flow of incubating companies created and supported by the Paragon Innovation Capital™ model. Since 2017, Paragon and its partners have invested more than $1 billion in its portfolio companies and expects ongoing investments of up to $500 million annually to address unmet need through life science breakthroughs. Throughout his career, Mr. Aronin has received numerous distinctions and honors for his entrepreneurship and dedication to life sciences. In 2020, he was named as one of the Top 10 Inspiring CEOs by Insights Success magazine. In 2018, he was named Innovator of the Year by Best in Biz Awards for his lifelong commitment to developing medicines for severe diseases. That same year, Insights Care named Mr. Aronin one of the 20 Most Influential Leaders in Healthcare. He was awarded the Weizmann Leadership Award in recognition of his work to improve patients’ lives through advancements in science and technology. Mr. Aronin has been inducted into the Chicago Entrepreneur Hall of Fame and was also honored with the EY Entrepreneur of the Year Award. Outside of Paragon, Mr. Aronin devotes his talents to civic and philanthropic endeavors. As founder and chairman of MATTER – a health-technology incubator to support innovators – Mr. Aronin has led one of Chicago’s most remarkable, philanthropic venture-innovation successes, with more than 200 healthcare companies at any one time, more than 60 corporate sponsors, and more than $1.7 billion in deals since 2015. He serves on several corporate and civic boards including Discover Financial Services and The Aspen Institute and is a member of The Commercial Club of Chicago. As a believer in education as a change agent, Mr. Aronin is a mentor to students and young professionals and is a frequent lecturer at the University of Chicago’s Booth School of Business and Northwestern University’s Kellogg School of Business.
Follow Jeff Aronin:
About Castle Creek Biosciences, Castle Creek Biosciences, Circ, Emalex Biosciences, Inc., Evozyne, Harmony Biosciences, Harmony Biosciences, Ovation Pharmaceuticals, Paragon Biosciences, Paragon Biosciences, Paragon Health Capital, Paragon Pharmaceuticals, Qlarity Imaging, Skyline Biosciences, Skyline Biosciences, The Aspen Institute, The University of Chicago Booth School of Business: Evozyne is a biotechnology company that specializes in protein design and molecular scale.
Edwin Kania
Managing Partner & Co-Founder; Chairman Emeritus of Flagship Pioneering
Edwin Kania is a Managing Partner and Co-Founder of Flagship Ventures and served as Chairman of the Board of Directors at Flagship Ventures between 2001 – 2014. Edwin has 33 years of experience in the venture capital industry. Prior to co-founding Flagship Ventures in 2000, Edwin spent 14 years as General Partner of OneLiberty Ventures and of its predecessor firm, Morgan, Holland Ventures. From 1983 – 1984 Edwin served as an Investment Officer at First Capital Corporation of Boston, the venture capital subsidiary of Bank of Boston and previously, as Research Associate at Harvard Business School and as General Manager at J. Cunningham, Inc. Edwin is a frequent speaker on venture capital and entrepreneurship. Edwin earned his undergraduate degree in Physics from Dartmouth College and his MBA from Harvard Business School. While at Dartmouth, Edwin was an All-American Track and Field athlete and a national and collegiate record holder. Throughout his professional career, Edwin has operated both as an investor and as an active partner to entrepreneurs in company building. Edwin’s direct investment experience covers over 100 companies. In addition, Edwin has been intimately involved in the launch and development of more than a dozen companies as the founding, lead or co-lead investor, and on occasion has assumed operating roles in support of management. Several of these companies are now publicly traded while others have been acquired by significant publicly-traded companies. The total value of the companies in which Ed has participated as founding or lead investor is currently several billion dollars. Among the companies for which Ed has served as an active Director are Acceleron Pharma (NASDAQ: XLRN), Adolor (NASDAQ: ADLR), Alere Corp. (purchased by Inverness Medical), Anesta Corp. (NASDAQ: NSTA, purchased by Cephalon), Aspect Medical (NASDAQ: ASPM, purchased by Covidien), AudioLogic (purchased by Cirrus Logic), ChemGenics Pharmaceuticals (purchased by Millennium), Cytyc Corp. (NASDAQ: CYTC), EXACT Sciences (NASDAQ: EXAS), Interactive Supercomputing (acquired by Microsoft), Ontogeny (merged into Curis, NASDAQ: CRIS), PerSeptive Biosystems (NASDAQ: PBIO, purchased by Applera), Somatogen (NASDAQ: SMTG, purchased by Baxter), and VisEn Medical (acquired by PerkinElmer). He was also a founding investor in IDEXX Laboratories (NASDAQ: IDXX) and in TripAdvisor (purchased by InterActive Corp). Currently, Edwin is a Director of Flagship portfolio companies EcoSense Lighting, Oasys Water, Selecta Biosciences, TARIS Biomedical, Tarveda Therapeutics, TransMedics and Visterra, as well as on the Board of DataCore Software. Edwin also serves on the Board of Common Impact, a non-profit organization that connects skilled professionals from global corporations to local, high potential non-profits. Edwin has been a long-time Member of the Board of Directors of MassBio, a not-for-profit organization representing theMassachusetts biopharmaceutical industry and serves as a Member of Harvard Partners’ Innovation Advisory Board and The Johns Hopkins Medicine Alliance for Science and Technology Development.
Follow Edwin Kania:
About Flagship Pioneering: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Shane J Schaffer
Chairman and CEO of Cingulate Therapeutics
Shane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and has served as the Chairman and CEO since its inception. Dr. Schaffer is an 18-year pharmaceutical industry veteran with experience in pharmaceutical drug development, commercialization and biotech commercial operations. During his career, he has held positions of increasing responsibility at Pfizer, Novartis and Sanofi (including predecessor companies). Dr. Schaffer has broad functional and therapeutic expertise through the development and commercialization of several billion dollar brands including the ADHD Franchise of Ritalin® & Focalin®, Lipitor®, Lyrica®, Eligard®, Arixtra®, Hyalgan® and Avapro®/Avalide®. He has led the strategic brand planning, franchise resource allocation and managed care & reimbursement strategy for numerous products. Dr. Schaffer received his Doctor of Pharmacy degree from the University of Kansas. He served as Chief Fellow and completed a Post-Doctoral Pharmaceutical Industry Fellowship at Rutgers University, College of Pharmacy in conjunction with Warner-Lambert/Parke-Davis, now Pfizer.
Follow Shane J Schaffer:
About Cingulate Therapeutics: Cingulate Therapeutics uses a unique combination of delivery technology and proven medications that creates an unmatched release profile.
Martin Shkreli
Founder & Executive Chairman of Turing Pharmaceuticals
Martin Shkreli is the founder and CEO of Turing Pharmaceuticals. He is the founder of Retrophin, LLC (the predecessor of Retrophin, Inc.) and former President of Retrophin, Inc. since its formation. Martin Shkreli is also the founder and managing partner of MSMB Capital Management, a New York hedge fund firm founded in 2006 that manages a variety of partnerships. Prior to MSMB, Martin Shkreli was employed at Intrepid Capital Management from 2004 to 2006 and previously at Cramer Berkowitz & Co, both of which are hedge fund firms based in New York. Martin Shkreli is an experienced biotechnology and pharmaceutical industry investor, particularly in businesses with orphan drugs. Martin Shkreli received his BBA from Baruch College.
Follow Martin Shkreli:
About Shkreli Foundation, Turing Pharmaceuticals: Turing Pharmaceuticals is a biopharmaceutical company focusing on patients with unmet medical needs.
James C. Katzaroff
CEO, Chairman and Founder of Vivos Inc
A serial entrepreneur who started his first company importing minerals and pewter from Brazil while in high school in southern California, Mr. Katzaroff is constantly searching for outstanding opportunities. Hired straight out of college Mr. Katzaroff was a financial consultant for Wall Street firms Bateman Eichler, Smith Barney and EFHutton. Since 1990, he has been responsible for corporate engineering, senior-level corporate strategy, fostering investment bank relationships, and has served as a senior financial advisor for numerous start-ups and development stage companies. A strong desire to make an unshakable impact in the fight against cancer led Mr. Katzaroff to found AMI in 2006.
Follow James C. Katzaroff:
About Vivos Inc: Vivos Inc develops manufacturing equipments for the production of medical isotopes used in diagnosis and treatment of diseases.
Rene Bharti
Founder & Executive Chairman of Future Fertility
Rene has held several key roles in both public and private companies, including those in the resource, technology and entertainment industry. Rene Bharti co-founded ARHT Media, along with legendary singer Paul Anka, with the aim of creating the worlds most lifelike digital humans to conduct e-commerce in a unique and viable platform. Rene Bharti holds a Bachelor of Commerce (Honors) from Queens University.
Follow Rene Bharti:
About Future Fertility, Spend: Future Fertility is a provider of artificial intelligence tools for reproductive medicine.
Howard Solomon
Chairman & CEO of Forest Laboratories
Mr. Howard Solomon has been the President of Clinical Data Inc. since April 13, 2011. Mr. Solomon has been the Non Executive Chairman and Senior Advisor of the Board of Forest Laboratories Inc. since October 1, 2013. He serves as the Chairman and Chief Executive Officer of Forest Pharmaceuticals, Inc. He began his career as an attorney at leading law firms in New York and joined Forest in 1964 as a director and secretary of the Board while serving as outside counsel for the Company. He served as the Chief Executive Officer of Forest Laboratories Inc. since 1977 until October 1, 2013, and served as its President until October 1, 2013. He serves as also served as the Chairman of Forest Laboratories Inc. He has been a Director of Forest Laboratories Inc. since 1964 and Clinical Data, Inc. since April 13, 2011. Mr. Solomon is a Trustee of the New York Presbyterian Hospital and previously served on the Board of Cold Spring Harbor Laboratories. He is a Member of the Executive Committee of the Board of Directors at the Metropolitan Opera and Chairman of its Finance Committee. He also serves on the Board of the New York City Ballet. Mr. Solomon graduated from the City College of New York and holds a J.D. from Yale University.
Follow Howard Solomon:
About Forest Laboratories: Forest Laboratories, Inc. (NYSE: FRX) is a U.S.-based pharmaceutical company with a long track record of building partnerships.
John Stuelpnagel
Co-Founder & Chairman of Fabric Genomics (formerly Omicia)
Dr. John Stuelpnagel currently serves as the Executive Chairman of Ariosa Diagnostic since 2009 and a board member at Sequenta, two leading genomic-based Diagnostic companies in the San Francisco bay area. Prior to this, John co-founded Illumina Inc., a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and biological function. John was involved in making Illumina one of the most successful life science companies, serving as its first President and Chief Executive Officer from 1998 to 1999, Vice President of Business Development from 1999 to 2002, Senior Vice President of Operations from 2002 to 2005 and Chief Operating Officer from January 2005 to April 2008. Prior, he was a venture capitalist at CW Group from 1997 to 1998 and with Catalyst Partners, a venture capital firm, from 1996 to 1997. While at CW Group, John uncovered what would become Illumina’s BeadArray technology at Tufts University and negotiated an exclusive license to that technology which led to the founding of Illumina Inc. He also served as a member of the Board of Directors of Illumina Inc. from April 1998 until April 2008. John received his B.S. in Biochemistry and his Doctorate in Veterinary Medicine from the University of California, Davis and his M.B.A. from the University of California, Los Angeles.
Follow John Stuelpnagel:
About Ariosa Diagnostics, Fabric Genomics (formerly Omicia): Global healthcare platform for genomics-driven precision medicine. Fabric’ proven AI algorithms power genomic insights.
Ethan D. Leder
Co-Founder, Partner & Executive Chairman of Precision Medicine Group
Ethan Leder is the Co-Founder and Executive Chairman of Precision Medicine Group. Over the past 25 years, he has been an entrepreneur focused on building and managing innovative, market-leading companies that address critical gaps in the healthcare industry. Prior to Precision Medicine Group, Leder was the Founder and CEO of United BioSource Corporation (UBC), which became the leader in real-world research addressing safety, value, and comparative effectiveness for the life science industry. UBC was acquired by Medco Health Solutions in late 2010 and is now part of Express Scripts. Before UBC, Ethan was the Co-Founder and CEO of U.S. Bioservices, Inc., which addressed a growing need for personalized, direct-to-patient distribution of high-cost biotechnology for serious medical conditions. U.S. Bioservices was acquired by AmerisourceBergen in 2002. Prior to U.S. Bioservices, he was the Founder and President of HealthCare Financial Partners, the leading specialty lender to the healthcare industry. It was acquired by GE Capital in late 1999. Ethan received his undergraduate degree from Johns Hopkins University and his Juris Doctor from Georgetown University Law Center. He also serves on the Board of Trustees of Johns Hopkins University and is active in many charitable and community development projects in the Washington DC, metropolitan area.
Follow Ethan D. Leder:
About Precision for Medicine, Precision Medicine Group: Precision Medicine Group accelerates values and improve outcomes for innovative pharmaceutical and life science companies.
Alex Dickinson
Chairman & Co-founder of ChromaCode
Follow Alex Dickinson:
About ChromaCode: ChromaCode is a molecular diagnostics company focusing on bioinformatics.
Alan Collier
Chairman & CEO of Endonovo Therapeutics
Alan Collier Chairman & Chief Executive Officer has more than twenty years of experience in corporate finance, IP development, telecommunications and technology with a concentration in healthcare and technology over the last five years. Prior to his appointment as Endonovo’s CEO and chairman, Mr. Collier served as CEO and director of IP Resources International, Inc. where he was instrumental in developing a platform for for the licensing and acquisition of life science and technology companies. Previously, Mr. Collier served as a Senior Managing Director at Mid-Market Securities, a FINRA-registered Broker-Dealer. Prior to joining Mid-Market Securities, Mr. Collier was a Managing Director at Mosaic capital and co-managed its Capital Markets Group. He was previously a Vice President at Corporate Capital Group and Managing Director and CEO of Greenbridge Capital Group. Over the progression of his career, he has specialized in the development and financing of early stage, high growth, and acquisitive companies (public and private). He has structured, participated in, and completed numerous transactions including mergers and acquisitions, equity and debt placements, capital restructuring, joint venture development, and channel partner procurement. He has held numerous board and executive positions throughout his career in the telecommunications, technology, specialty finance, corporate finance and healthcare industries. Mr. Collier holds FINRA Series 7, 79, 63, and 24 Licenses.
Follow Alan Collier:
About Endonovo Therapeutics, IP Resources International: Endonovo Therapeutics is a biotechnology company developing off-the-shelf regenerative products.
David Adair
Founder & Chairman of Glenveigh Medical
C. David Adair, MD (Chairman and CSO) is a board certified maternal-fetal medicine specialist and president of Regional Obstetrical Consultants, an MFM practice with over 50 employees and offices in Chattanooga, Tennessee. Dr Adair is Professor and also serves as Vice-Chairman, Obstetrics and Gynecology, University of Tennessee College of Medicine. He has more than 50 publications and more than 20 teaching/research awards, including 4 Best Research Awards for Clinical Obstetrics. Dr Adair received his undergraduate degree in biological sciences at Morehead State University, his medical degree from Marshall University, residency in Obstetrics and Gynecology at the University of Florida Health Science Center, Jacksonville, and fellowship in Maternal-Fetal Medicine at Wake Forest University. He received extern training at Henry Ford Hospital, National Maternity Hospital, Dublin, Ireland, and at the Renal Unit Mass General Hospital.
Follow David Adair:
About Glenveigh Medical, Solas BioVentures: Glenveigh Medical is a life science and medical technology company that focuses on advancing the practice of obstetrics.
Bill Cherman
Co-Founder and Chairman of Repair Biotechnologies
Bill is co-founder and Chairman of Repair Biotechnologies. He is a Partner at Front Seat Capital, where he leads investments in biotech and blockchain. Previously, he was a consultant at McKinsey & Company. Bill is a student of the Master of Biotechnology Enterprise and Entrepreneurship at Johns Hopkins University, and has a B.A. in Economics from PUC-Rio.
Follow Bill Cherman:
About Repair Biotechnologies: Repair Biotechnologies is a biotechnology company with the mission to develop and bring to the clinic therapies.
Edward Schulak
Chairman of EdenRoc Sciences
Follow Edward Schulak:
About : EdenRoc Sciences is a privately backed holding or operating company managing bioscience and pharmaceutical startup companies.
Robert J. Coury
Executive Chairman of Viatris
Robert J. Coury is the executive chairman of Viatris. Since 1995, when he was first hired as a strategic adviser to Mylan, Coury has held various leadership positions at the company. He is also the founder and president of the Robert J. Coury Family Foundation, a private foundation formed to give back and support his philanthropic efforts. After serving as a strategic adviser to Mylan for close to 7 years, Coury was elected to the company’s board of directors in February 2002. Soon after, he became the board’s vice chairman and was named the chief executive officer in September 2002. Coury served as CEO until January 2012 when he became the company’s executive chairman. He would stay in this role for 4 years before becoming chairman in June 2016. Under Coury’s dedicated leadership at Mylan, the company became one of the largest pharmaceutical companies in the world, with positions in both the S&P 500 and the Fortune 500 (the latter prior to the company’s reincorporation outside of the United States in 2015). Coury guided Mylan through transactions that totaled approximately $25 billion and resulted in a large portfolio of products sold in over 165 countries and territories. With a global workforce of close to 35,000, Mylan has become an international powerhouse with a high quality foundation to build upon moving forward. Most recently, Coury’s stepped up once again, being named Executive Chairman for the second time, so that he could offer the leadership needed for Mylan and Upjohn a division of Pfizer to combine and form Viatris in 2020. With its Global Healthcare Gateway™, Viatris continues to build on Coury’s vision and outstanding record of success. The company is positioned with unmatched global infrastructure and expertise. The Global Healthcare Gateway™ enables Viatris to offer opportunities to small and mid size biotech among other regional companies to quickly reach global markets leveraging Viatris’s existing infrastructure. As the executive chairman of Viatris, Coury mentors and drives the management team to execute the company’s strategy, leads the board of directors, and propels the strategic direction of the company for continued success in the global marketplace.
Follow Robert J. Coury:
About Viatris: Viatris is a global pharmaceutical company formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer.
Josiah Hornblower
Founder & Executive Chairman of Shattuck Labs
In addition to serving as Managing Member of Pilgrims & Indians, Josiah has been a Managing Member of Blue Pine Partners, LLC since 2008, an investment and advisory firm that he founded in the community bank sector. From 2004 to 2008, Josiah was a principal of Resource Financial Institutions Group, Inc. (RFIG), a manager of private equity funds focused on investing in community banks. During that period, he served on the Board of Directors of Pacific Enterprise Bancorp, an Orange County, California-based commercial bank. Before joining RFIG, Josiah worked as an equity analyst at Gray Seifert and Co., an investment management firm specializing in financial services, and at Barrett Associates, Inc. At both firms, he researched and invested in regional banks and financial technology companies. Josiah was a director of Portland, Oregon-based Capital Pacific Bank until its purchase by Pacific Continental Corporation (NASDAQ: PCBK) in 2015. Josiah currently serves on the boards of Pelican Therapeutics, Inc. and Population Diagnostics, Inc, and serves as CEO of Shattuck Labs, Inc. Josiah graduated with a Bachelor of Arts degree from Trinity College and was a member of Phi Beta Kappa. He resides in Austin, Texas.
Follow Josiah Hornblower:
About Blue Pine Partners, Pelican Therapeutics, Shattuck Labs: Shattuck Labs is a biotechnology company that provides novel class biologic medicines for the treatment of cancer and autoimmune disease.
Bruce Booth
Chairman of the Board of Kymera Therapeutics
Bruce is a Co-Founder and the Chairman of the Board at Kymera Therapeutics. He’s also a partner at Atlas Venture and focuses on the discovery and development of novel therapeutics. Since joining in 2005, Bruce has been instrumental in forming unique, innovative, and capital-efficient structures for drug discovery and development. He is a co-founder/founding investor and currently chair of the board of miRagen Therapeutics, Nimbus Therapeutics, Padlock Therapeutics, Quartet Medicine, and Rodin Therapeutics. Along with Peter Barrett, Bruce seeded, incubated, and serves on the board of Zafgen (NASDAQ: ZFGN), and Bruce is a board member of Lysosomal Therapeutics Inc. (LTI) and Unum Therapeutics. Previously, he served on the boards of past Atlas companies Avila Therapeutics (acquired by Celgene), Stromedix (acquired by Biogen), Prestwick (acquired by Biovail), and Proprius (acquired by Cypress Biosciences), among others. Previously, Bruce was a principal at Caxton Health Holdings L.L.C., a healthcare-focused investment firm, where he focused on the firm’s private equity activities, ranging from early-stage venture capital through late-stage buyouts. Prior to Caxton, he was an associate principal at McKinsey & Company, a global strategic management consulting firm, where he advised clients on R&D productivity, corporate strategy and business development issues across the biopharmaceutical sector. Bruce currently serves as a trustee of the New York Academy of Medicine and is a term member of the council on foreign relations. He received a DPhil from Oxford University as a Marshall Scholar and a BS from the Pennsylvania State University.
Follow Bruce Booth:
About Atlas Venture, Nimbus Therapeutics: Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
Hugh Grant
Chairman and Chief Executive Officer of Monsanto
Hugh Grant is President and Chief Executive Officer at Monsanto.
Follow Hugh Grant:
About Monsanto: Monsanto Company is a multinational chemical and agricultural biotechnology corporation that provides agricultural products for farmers.
Joshua Boger
Executive Chairman of Alkeus Pharmaceuticals
Dr. Joshua Boger is the founder and former CEO of Vertex Pharmaceuticals Incorporated. He served in the additional role of Chairman of the Board from 1997 until 2006, and currently serves as a Board Member. Dr. Boger served as Vertex’s Chief Scientific Officer from 1989 until 1992 and has been a Director since Vertex’s inception. Dr. Boger served as Chairman of Bio, the Biotechnology Industry Organization, from 2007-2009. Dr. Boger holds a B.A. in chemistry and in philosophy from Wesleyan University and M.S. and Ph.D. degrees in chemistry from Harvard University. His postdoctoral research in molecular recognition was performed in the laboratories of the Nobel-prize winning chemist, Jean-Marie Lehn in Strasbourg, France. Prior to founding Vertex in 1989, Dr. Boger held the position of Senior Director of Basic Chemistry at Merck Sharp & Dohme Research Laboratories in Rahway, New Jersey, where he headed both the Department of Medicinal Chemistry of Immunology & Inflammation and the Department of Biophysical Chemistry.
Follow Joshua Boger:
About Alkeus Pharmaceuticals: Alkeus Pharmaceuticals Inc., a Boston-based startup focused on treatments for serious ophthalmic conditions.
Pratik Shah
Executive Chairman & Co-Founder of Design Therapeutics
Pratik Shah is the Co-Founder and Executive Chairman of Design Therapeutics.
Follow Pratik Shah:
About CNS Therapeutics (Old), Design Therapeutics: Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders.
Amy Schulman
Executive Chairman & Co-Founder of Lyndra Therapeutics
Amy Schulman is the Chief Executive Officer at Arsia Therapeutics since August 2014. Arsia, a biotechnology company focused on improving patients’ lives through new modes of drug delivery, and a venture partner at Polaris, a leading venture capital firm with approximately 4 billion under management in August of 2014. Amy joined Polaris Partner’s Boston office as a Healthcare Venture Partner in 2014, simultaneously assuming the role of Chief Executive Officer of Arsia Therapeutics, a Polaris-backed company. In July 2015 Amy co-founded Lyndra where she is Chief Executive Officer and President. Amy is an accomplished business leader, widely recognized for growing and stabilizing global businesses, commitment to people, strategic judgment, and efforts to advance women and promote inclusive workplace cultures. Amy joined Harvard Business School’s Faculty as a Senior Lecturer in July 2014. Prior to that, Amy led Pfizer Inc.’s $4 billion Consumer Healthcare business, which operates in 90 countries and includes well-known brands such as Advil, Centrum and Chapstick. Amy also served as Executive Vice President and General Counsel of Pfizer Inc. Key accomplishments include: revitalization of the ChapStick brand; regulatory filing for Lipitor OTC; rapid growth of Emergen-C and increased Europe profitability. Amy originally joined Pfizer in 2008 as General Counsel and saw the company through its $68 billion acquisition of Wyeth, the largest pharmaceutical acquisition in history. In 2009, Amy spearheaded an innovative approach to engaging outside counsel and became recognized as a leading voice for transforming the billable-hour model and for redefining the value of legal services. Before joining Pfizer, Amy was a Partner at DLA Piper, where she was a Member of the Board and Executive Policy Committees and built and led the international law firm’s mass tort and class-action practice handling some of the most complex legal, scientific and regulatory challenges facing the world’s largest and most reputable companies, including Kraft, Altria, Cisco, GE Healthcare and Pfizer. Amy began her career in litigation with Cleary Gottlieb Steen & Hamilton. Amy’s accomplishments have earned her accolades from leading publications and organizations. In 2013 Fortune magazine named her one of the “50 Most Powerful Women in Business.” That same year, The American Lawyer named her one of the “Top 50 Innovators,” and The National Law Journal named her one of “The 100 Most Influential Lawyers in America.” Amy also has been recognized by The American Bar Association, which honored her with the Margaret Brent Women Lawyers of Achievement award in 2012. In 2009 Forbes magazine included her on its inaugural list of “The World’s Most Powerful Women.” Amy serves on the Boards of Directors of Alnylam Pharmaceuticals, Arsanis, Biosciences, Arsia Therapeutics, BIND Therapeutics, Blue Buffalo, Lyndra, and SQZ Biotech. A Phi Beta Kappa Graduate of Wesleyan University, Amy earned her J.D. from Yale Law School in 1989.
Follow Amy Schulman:
About Arsia Therapeutics, Harvard Business School, Lyndra Therapeutics, Polaris Partners, Suono Bio: Lyndra Therapeutics is a novel technology platform reinventing medicine for a healthier world.
Miles White
Executive Chairman of the Board of Abbott
Follow Miles White:
About Abbott, Abbott, The American Academy of Arts & Sciences: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
Paul Garofolo
Co-Founder, Chief Executive Officer, & Chairman of the Board of Locus Biosciences
Paul has been a member of multiple Executive Management teams of both publically traded multi-national corporations and successful startup opportunities. He currently serves as the CEO of Locus Biosciences, an emerging biotech focused on the discovery and development of a novel class of CRISPR/Cas Antimicrobials. Paul also serves as Vice President of the Friends Board at the North Carolina Museum of Natural Sciences, and as a Visiting Professor at North Carolina State University’s Poole College of Management. He serves as an executive-in-residence for the HiTEC Graduate Program, the University’s Entrepreneurship Collaborative.
Follow Paul Garofolo:
About Locus Biosciences: Locus Biosciences develops CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease.
Cameron Teitelman
Founder, Chairman, and head of admissions and oversee investment vehicles of StartX (Stanford-StartX Fund)
Cameron Teitelman is the Founder and Chairman of StartX, a 501 (c)(3) nonprofit that runs an accelerator for Stanford affiliated entrepreneurs. Under his management, StartX has supported more than 1,100+ founders building 500+ companies. StartX companies have raised over $3.3B to date. In 2013, the Stanford-StartX Fund was launched. To date, SSF has invested in 250 StartX companies across 400+ rounds, investing $130 million in capital.
Follow Cameron Teitelman:
About StartX (Stanford-StartX Fund): StartX is an educational non-profit that helps Stanford’s top entrepreneurs.
Samuel D. Waksal
Founder & Chairman of MeiraGTx
Follow Samuel D. Waksal:
About Brain-Mind Institute, Graviton, MeiraGTx, Weill Cornell Medicine: Meira Gene Therapy is a clinical-stage company developing novel treatments for inherited and acquired genetic disorders.
William C. Wortman
Director and Chairman of Exact Imaging
Mr. Wortman has been a director of Imagistx since April 2009. Mr. Wortman is presently a co-owner of Millennium Gaming. Inc. (MGI). MGI is the majority owner of Cannery Casino Resorts which owns and operates the Rampart Casino, Cannery Casino & Hotel and Eastside Cannery Casino & Hotel in Las Vegas and the Meadows Racetrack & Casino in Pennsylvania. Mr. Wortman began his career as an accountant with Laventhol & Horwath in 1974. In 1978 he joined Caesars Palace as financial controller and during the next six years, held various executive positions and though his efforts helped establish the Caesars brand as an industry leader. In 1983, Mr. Wortman purchased the Fallon Nugget and the Bonanza Inn and operated them until he sold them in 1996. In 1985, he purchased a substantial equity position in Nevada Palace in Las Vegas, a facility that was involved in a bankruptcy proceeding. Mr. Wortman, as managing partner assumed operating control restoring the facility to profitability. In 2006, Nevada Palace was sold to Cannery Casino Resorts. In addition to Imagistx, Mr. Wortman currently serves as a member of the UNLV Foundation Board of Trustees, board member of the UNLV Graduate School of Business, Board of Directors for Meadows Bank and the UNLV Leadership Campaign Committee. Mr. Wortman was the 1986 recipient of the Alumni of the Year Award for UNLV. Mr. Wortman received his Bachelor of Science in Accounting from UNLV.
Follow William C. Wortman:
About Cannery Casino Resorts LLC, Exact Imaging, Millennium Gaming. Inc: Exact Imaging is the developer of the ExactVu™ system, the first micro-ultrasound operating at 29 MHz that provides unmatched resolution.
Vicki Sato
Chairman of Vir Biotechnology
Vicki L. Sato, Ph.D., serves as chairman of the board of directors at Vir. Dr. Sato is also a professor of management practice at Harvard Business School, and an affiliate member of the Department of Molecular and Cell Biology, Harvard University. She has taught in HBS Executive Education programs and is a business advisor to enterprises in the biotechnology and pharmaceutical industries. Dr. Sato retired in 2005 from Vertex Pharmaceuticals, where she served as president since 2000, with responsibility for research and development, business and corporate development, commercial operations, legal, and finance. Prior to becoming president, she was chief scientific officer, senior vice president of research and development, and chair of the Scientific Advisory Board. Under her leadership, Vertex created a diversified pipeline of drugs. Before joining Vertex, Dr. Sato was vice president of research at Biogen, Inc., where she led research programs in the areas of inflammation, thrombosis, and HIV disease, and she participated in the executive management of the company. Several molecules from those programs have now reached the marketplace. She also served as a member of the Biogen Scientific Board. Currently, Dr. Sato is a member of the board of directors of publicly held companies Bristol Myers Squibb Company, PerkinElmer Corporation, Borg Warner Corporation, and Syros Pharmaceuticals. She also serves as chair of the board of directors for Denali. Previously, Dr. Sato has served as an overseer of the Isabella Stewart Gardner Museum. She received her A.B. from Radcliffe College, and her A.M. and Ph.D. degrees from Harvard University. Following postdoctoral work at both the University of California Berkeley and Stanford Medical Center, Dr. Sato was appointed to the faculty of Harvard University, where she was an assistant and associate professor of biology.
Follow Vicki Sato:
About : Vir Biotechnology is a clinical-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases.
Steve Papermaster
Chairman & CEO of Nano Cures
CEO & Chairman of Nano Steve is a technology entrepreneur and public policy expert who is highly experienced in founding, growing and funding innovative technology companies around the world. Steve spent two terms in the White House serving as a senior advisor to former U.S. President George W. Bush on domestic and global strategy for innovation, technology healthcare and science. As a presidential advisor, he helped lead the National Nanotechnology Initiative, the Human Genome Project and the White House Fellow, one of America’s most prestigious programs for leadership and public service. He has founded, led or served as a board member for several private and publicly traded companies, including LabNow, Moxie, Medaphis, Powershift Group, ROME Corp. (acquired by TriplePoint Technologies), TechRepublic (acquired by CNET Networks), Perficient (NASDAQ: PRFT), Vignette Corp. (NASDAQ:OTXT), Per Se Technologies (NYSE: MCK), Tipping Point Technologies (NASDAQ: HP), Novell and BSG Corp. Steve is a recipient of the Ernst & Young “Entrepreneur of the Year” award co-founded the “World Entrepreneur of the Year.” He co-authored the book “Smart Life,” a guide to technology innovation that drives major social changes around the world.
Follow Steve Papermaster:
About Nano Cures, Nano Vision, Powershift Group: Nano Cures is clinical-stage biotechnology and infectious disease immunity platform company.
Christoph Westphal
Founder & Executive Chairman of Verastem Oncology
Christoph Westphal is the Co-Founder, Chairman & Board Member at ImmuneID.
Follow Christoph Westphal:
About ImmuneID, Longwood Fund, Longwood Fund, Verastem Oncology: Verastem is a biopharmaceutical company that focuses on discovering and developing novel drugs that selectively target cancer stem cells.
Michael T. Heffernan
President , CEO & Chairman of the Board of Collegium Pharmaceutical
Michael Heffernan has 25 years of experience in the pharmaceutical and related healthcare industries. He is currently Co-Founder, President, CEO of Collegium Pharmaceutical. Collegium is specialty pharmaceutical company focused on the development of pharmaceutical products for the treatment of chronic pain. He was also previously the founder, President and CEO of Onset Therapeutics, a dermatology focused company that develops and commercializes products for the treatment of skin related illnesses and was responsible for the spin-off of this business to create PreCision Dermatology. Michael held prior positions as Co-Founder, President and CEO of Clinical Studies Ltd., a pharmaceutical contract research organization that he successfully sold. He also served as President and CEO of PhyMatrix, a public $400 million integrated healthcare services company where he was hired to restructure the company. Michael started his career at Eli Lilly and Company and served in numerous sales and marketing roles. He has also been a member of the Board of Directors, Advisor and Angel Investor in a number of healthcare companies. He is currently a member of the Board of Directors of TyRx, a venture backed medical device company, Cornerstone Therapeutics (NASDAQ:CRTX), a specialty pharmaceutical company and PreCision Dermatology. Michael earned his B.S. Degree in Pharmacy from the University of Connecticut and is a Registered Pharmacist.
Follow Michael T. Heffernan:
About AvengeBio, Collegium Pharmaceutical: Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of products for the treatment of chronic pain.
Maurice Ferre, M.D.
CEO & Chairman of InSightec
Dr. Maurice R. Ferré was the founding President and Chief Executive Officer of MAKO Surgical Corp, serving from 2004 until the acquisition of the company by Stryker Corp. for $1.7 billion in 2014. In June 2007, Dr. Ferré received the Ernst & Young Entrepreneur of the Year 2007 award for emerging companies in Florida. In 1993, he founded Visualization Technology, Inc., a medical device company for image-guided surgery, where he served as Chief Executive Officer until 2002 when the company was acquired by GE Healthcare, the healthcare division of the General Electric Company. Dr. Ferré served as Vice President of Strategic Development for GE Navigation, a Division of GE Healthcare, until 2004. Dr. Ferré holds an M.D. and a Master’s degree in Public Health from Boston University.
Follow Maurice Ferre, M.D.:
About DermaSensor, InSightec: InSightec develops and manufactures MR-guided Focused Ultrasound technology devices for image-guided acoustic surgery.
Stephen Kaldor
Co-Founder and Chairman of XinThera
Steve is a Venture Partner with Versant Ventures and is also the CEO of Quanticel Pharmaceuticals, a privately held Versant portfolio company focused on cancer drug discovery. Steve was CEO of Ambrx from 2007-2010 and helped this biologics company mature its drug portfolio and platform through deals with Pfizer, Merck, Lilly, and Merck-Serono. Steve served as President & CSO of Syrrx from 2002-2005, and led the company through its $270M acquisition by Takeda in 2005 and for several years post acquisition. Prior to joining Syrrx, Steve gained 12 years of R&D experience at Eli Lilly as both a researcher and Director. A chemist by training, Steve is a co-inventor of ten therapeutic compounds that have entered the clinic including Viracept, a marketed AIDS medication, and Nesina, a marketed diabetes medication. Steve also serves as an independent board member for various companies including Furiex (2010 – current), Amira (2008 through 2011 acquisition by BMS) and Anaphore (2008 – 2011). He received a PhD from Harvard University and a BA from Columbia University.
Follow Stephen Kaldor:
About XinThera: XinThera is a drug discovery company focused on building small molecule oncology and immunology pipeline.
Edward Ludwig
Non-Executive Chairman of the Board of Directors of POCARED Diagnostics
Edward Ludwig has been a Member of the Board of Directors of Boston Scientific since March 2014. Edward is the former Chairman of the Board of Directors of Becton, Dickinson and Company (“BDX”), a global medical technology company, having served in that position from February 2002 through June 2012. Edward also served as BDX’s Chief Executive Officer from January 2000 to September 2011 and as its President from May 1999 to December 2008. Edward joined BDX as a Senior Financial Analyst in 1979. Prior to joining BDX, Edward served as a Senior Auditor with Coopers and Lybrand (now PricewaterhouseCoopers) where he earned his CPA and as a financial and strategic analyst at Kidde, Inc. Edward serves as Lead Director on Aetna Inc.’s Board of Directors and chairs its Finance Committee and is a Member of the Board of Directors of Xylem, Inc. Edward serves as the Non-Executive Chairman of POCARED, a privately held firm in Israel. Edward is also a Member of the Board of The Center for Higher Ambition Leadership, which is dedicated to studying, documenting and advancing the principals of Higher Ambition Leadership that drive the most successful enterprises in terms of longer term shared value creation. Edward served as a Member of the Board of Trustees of the College of the Holy Cross (2005-2013), and the Columbia Business School Board of Overseers (2010-2015). Edward also served as a Member of the Board of Trustees of the Hackensack University Medical Center Network Board of Trustees. Edward received a B.A. degree in Economics and Accounting from The College of the Holy Cross and a MBA degree from Columbia University.
Follow Edward Ludwig:
About : Revolutionizing infections disease practice with culture-free microbiology.
Tony Coles
Chairman and CEO of Yumanity Therapeutics
Anthony Coles was named Chairman and Chief Executive Officer of Yumanity Therapeutics, LLC, a company focused on transforming drug discovery for neurodegenerative diseases, in October 2014. Prior to this, from October 2013, Anthony Coles served as Chairman and CEO of TRATE Enterprises LLC, a privately-held company. Anthony Coles served as President, Chief Executive Officer and Chairman of the Board of Onyx Pharmaceuticals, Inc., a biopharmaceutical company (“Onyx”), from 2012 until 2013, having served as its President, Chief Executive Officer and a member of its board of directors from 2008 until 2012. Prior to joining Onyx in 2008, he was President, Chief Executive Officer and a member of the board of directors of NPS Pharmaceuticals, Inc., a public biopharmaceutical company (“NPS”). Before joining NPS in 2005, he served in various leadership positions in the biopharmaceutical and pharmaceutical industries, including at Merck & Co., Inc., Bristol-Myers Squibb Company and Vertex Pharmaceuticals Incorporated. In addition to having previously served as a director of Onyx and NPS, he was formerly a director of Laboratory Corporation of America Holdings and Campus Crest Communities, Inc. Anthony Coles has been a director of the Company since April 2014. He is a member of the Compensation Committee and the Finance Committee.
Follow Tony Coles:
About Yumanity Therapeutics: Yumanity Therapeutics is a biotechnology company that transforms drug discovery for diseases caused by protein misfolding.
Jonathan Lim
Chairman & Co-Founder of Boundless Bio
Jonathan Lim is Founder of Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company that is a portfolio company of City Hill Ventures, LLC, a health care investment firm that he founded in 2010. Jonathan is also a Board Director of Bionomics Ltd (ASX: BNO). Prior to Ignyta, Jonathan’s experience includes Chairman, CEO and co-founder of Eclipse Therapeutics, Inc.; President and CEO of Halozyme Therapeutics, Inc. (Nasdaq: HALO); management consultant at McKinsey; NIH Postdoctoral Fellow at Harvard Medical School; and general surgery resident at New York Hospital-Cornell. In addition to serving on the Bio-X Advisory Council, Jonathan has been actively involved with his class reunion campaigns and other Stanford related activities. Jonathan has a B.S and M.S. from Stanford in Biological Sciences, an M.D. from McGill University and an M.P.H. from Harvard. Jonathan lives in San Diego with his wife, Dr. Conyee Tsai Lim (BA ’93), and their three children.
Follow Jonathan Lim:
About ARCH Venture Partners, Boundless Bio, City Hill Ventures, Erasca: Boundless Bio is a precision oncology company developing therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers.
Andrey Trapeznikov
Deputy Chairman of the Board for External Communications of RUSNANO
Follow Andrey Trapeznikov:
About : Rusnano is a joint-stock company aimed at commercializing developments in the nanotechnology industry.
Ira Pastor
Chairman of Bioquark
25 years of experience across multiple sectors of the pharmaceutical industry including pharmaceutical commercialization, biotech drug development, managed care, distribution, OTC, and retail; Served as VP, Business Development for drug development company Phytomedics Inc., raising $40 million of private equity, consummating over $50 million of licensing deals, and bringing lead drug candidate from discovery stage to Phase III development; Prior to that, employed by SmithKline Beecham Pharmaceuticals working in sales, marketing, and business strategy positions. Mr. Pastor has also served as Vice President of Corporate Development for the pharmacy benefit management company Prescription Delivery Systems (acquired by Cigna Health Insurance); MBA, Temple University; BS, Pharmacy, Rutgers University.
Follow Ira Pastor:
About Bioquark, Progress, Potential, And Possibilities: Bioquark is a life science firm developing proprietary combinatorial biologic products for both the regeneration & repair of human organs.
Gadi Maier
Chairman and President of Monterey Bay Labs
As a seasoned hi-tech executive and entrepreneur, Gadi Maier leads the business and the organization as CEO of FreeMonee. Prior to this role, Gadi served as president and CEO of FraudSciences Corporation; as a partner at Pinnacle Ventures and Benchmark Capital; co-founder and CEO of Scalent Systems; co-founder and CEO of Currenex; CEO of GetThere Inc. and CEO of Memco Inc. In addition, he held senior-level management positions at both Cisco and Oracle.
Follow Gadi Maier:
About Monterey Bay Labs: Monterey Bay Labs InoCyte technology, is a natural, marine extracted microinjection delivery platform that accelerates.
Marshal Linder
Chairman, CEO of Breethe
Marshal Linder is the Chairman and CEO of Breethe, Inc.
Follow Marshal Linder:
About Breethe: Breethe is a medical device company that develops a compact artificial lung for patients with acute and chronic lung problems.
James Sapirstein
Chairman, CEO and President of First Wave BioPharma
Mr. Sapirstein is a start-up and turnaround specialist with 30 years of pharmaceutical and biotechnology industry experience. Most recently, he served in key leadership positions at Gilead Sciences, Serono Laboratories, and Tobira Therapeutics. Beginning in 2000, Mr. Sapirstein led and developed the global marketing strategy for Gilead’s flagship HIV drug Viread. He played an instrumental role in the development of the drug combination strategy that resulted in Gilead’s acquisition of Triangle’s nucleoside portfolio. In 2002, he accepted the position of Executive Vice President for Serono Laboratories where he led a team of over 100 professionals to rebuild a struggling HIV and pediatric growth hormone business. In this role, he increased sales of Serono’s products several fold, while forging the U.S. commercialization of Serostim and Saizen. As CEO of privately held Tobira Therapeutics, a New Jersey-based biopharmaceutical company focused on the development of novel HIV and infectious disease compounds, he was instrumental in helping to raise over $60 million in venture capital and research funding. Mr. Sapirstein is a graduate of the Rutgers University Ernest Mario School of Pharmacy and recieved an MBA from Fairleigh Dickinson University.
Follow James Sapirstein:
About First Wave BioPharma, Hepion Pharmaceuticals: First Wave BioPharma aims to become a leader in developing non-systemic, recombinant protein therapies.
Matthew Emmens
Chairman of the Board of Director of Vertex Pharmaceuticals
Matthew was appointed Chairman on June 18, 2008 and has been a member of the Board since March 12, 2003.He is also a member of the Nomination Committee. He was the Company’s Chief Executive Officer from March 2003 to June 2008.Matthew brings to the Board his operational knowledge of Shire and his wealth of international sales, marketing, integration and operational experience in the pharmaceutical sector. Matthew is a Director of Vertex Pharmaceuticals Inc.He served as Chairman, CEO and President of Vertex Pharmaceuticals Inc. from 2009 until early 2012 and is a former Director of Incyte Corporation.
Follow Matthew Emmens:
About : Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
Gregory A. Demopulos
Chairman and Chief Executive Officer of Omeros
Gregory A. Demopulos, M.D. is one of our founders and has served as our President, Chief Executive Officer and Chairman of the Board of Directors since June 1994. Prior to founding Omeros, Dr. Demopulos completed his residency in orthopedic surgery at Stanford University and his fellowship training at Duke University. Dr. Demopulos received his M.D. from the Stanford University School of Medicine and his B.S. from Stanford University.
Follow Gregory A. Demopulos:
About Omeros: Omeros is a clinical-stage biopharmaceutical company developing products focused on inflammation and central nervous system disorders.
Thomas Yuen
Chairman, President and CEO of PrimeGen Biotech
Tom Yuen is a proven serial entrepreneur who has founded several successful publicly traded companies including AST Research Inc. and SRS Labs, Inc. (NASDAQ: SRSL). Tom Yuen received his Bachelor of Science degree in Electrical Engineering from the University of California, Irvine in 1974. Tom Yuen Has received many honors including: Director of the Year, Orange County Forum for Corporate Directors (1997), Top 25 Executives, Consumer Industry, Computer Reseller News Magazine (1991 & 1987), The UCI Medal (1990), The UCI Outstanding Engineering Alumni Award (1987), and The UCI Distinguished Alumnus Award (1986).
Follow Thomas Yuen:
About PrimeGen Biotech: PrimeGen Biotech is a privately held stem cell research company dedicated to optimizing the therapeutic potential of adult stem cells.
Guy Miller
Chairman, CEO & Co-Founder of Edison Pharmaceuticals
Guy Miller, MD, PhD is the co-founder of Edison Pharmaceuticals, and has served as Chairman and Chief Executive Officer of the Board since 2005. Prior to founding Edison, he founded Galileo Pharmaceuticals, a biopharmaceutical company, and was its Chairman and CEO from 1995-2005. Dr. Miller holds an MD from the Medical College of Pennsylvania and a PhD in chemistry from the University of Virginia. He completed his surgical internship at the University of Chicago, and a residency in anesthesiology and critical care medicine at Johns Hopkins. Dr. Miller completed a fellowship in multidisciplinary critical care medicine at Johns Hopkins, where he was on the faculty as an Assistant Professor until 1996. He is currently an attending physician in medical-surgical critical care medicine at Stanford University-PAVAMC.
Follow Guy Miller:
About Ampere Life Sciences, BioElectron Technology Corporation, Edison Pharmaceuticals, Stanford University School of Medicine: Edison Pharmaceuticals develops medicines for the treatments of children and adults diagnosed with rare and neglected diseases.
Victor Perlroth
Chairman & CEO of Kodiak Sciences
Victor Perlroth co-founded Kodiak Sciences in 2009 and is the company’s Chairman and Chief Executive Officer. Together with a talented core team, he has built Kodiak on a foundation of scientific excellence with a simple mission—to design and develop novel medicines for highly prevalent diseases. Under Perlroth’s leadership, Kodiak is building a pipeline of potentially life transforming ophthalmology drug candidates. Previously, Perlroth served as Venture Partner and then Entrepreneur in Residence at MPM Capital, a dedicated healthcare venture capital investment firm. In 2003, Perlroth co-founded Avidia, a biopharmaceuticals drug discovery and development company where he served as General Manager and Vice President of Corporate Development. In this role, at various times he had broad management responsibility across both corporate and research and development activities. Perlroth was one of two principals involved in the acquisition of the company by Amgen for $450 million. Earlier, Perlroth worked at Guzik Technical Enterprises, the industry-leading provider of test equipment to the hard disk drive industry, where he was Chief Operating Officer. Perlroth earned his M.D. and M.B.A. degrees from Stanford University and an A.B. in Molecular Biology summa cum laude from Princeton University.
Follow Victor Perlroth:
About Kodiak Sciences: Kodiak is designing and developing novel therapies for the treatment of retinal disease.
David M. Geliebter
Executive Chairman & Co-Founder of Remedy Pharmaceuticals
David is a co-founder of Remedy Pharmaceuticals. A serial entrepreneur, he has over 50 years of experience successfully starting and growing several businesses. David founded and ran the Carson Group, a global financial information and advisory company, which was sold to Thomson Corporation in 2000. He was also a founding principal and President of Evolution Capital, a healthcare investment banking firm. Prior to that, David founded Harvard Capital, a financial communications company that was acquired by WPP Group in 1986. David is the Managing Partner of Carrot Capital Healthcare Ventures and founder and board member of Critical Diagnostics, a diagnostics company focused on cardiac disease. David is a past winner of the Ernst & Young Entrepreneur of the Year Award.
Follow David M. Geliebter:
About Critical Diagnostics, Embark Healthcare, Flat Squirrel Press, Learmont Pharmaceuticals, Martin Pharmaceuticals, Remedy Pharmaceuticals, Woolsey Pharmaceuticals: Remedy Pharmaceuticals is a clinical stage pharmaceutical company that develops molecule drugs for acute central nervous system disorders.
Jon Vein
Co-Founder and Chairman of BiologyWorks
Follow Jon Vein:
About BiologyWorks: Creating useful data using advanced tech in chemistry, molecular biology, electrical engineering, and computer science.
J. Kurt Jacobus
Chairman and CEO of Restor3d
Kurt Jacobus is a Managing Director of the GRA Venture Fund.
Follow J. Kurt Jacobus:
About Restor3d: Restor3d offers surgeons with biomaterials, 3D printing technologies, and artificial intelligence to repair and rebuild the human body.
Allan Camaisa
Chairman, CEO, and Founder of Calidi Biotherapeutics
Allan Camaisa is a serial entrepreneur, investor, and technologist, with proven leadership skills in bootstrapping start-ups. He has had four successful exits, which were sold to publicly traded Fortune 1000 companies with tremendous shareholder returns. Since taking over as Chairman and CEO of Calidi Biotherapeutics, he has made a number of advancements, including a partnership with the U.S. NIH, recruitment of a Scientific Advisory Board, and the engagement of license negotiations with large pharmaceutical organizations, among others. Several years ago, Mr. Camaisa lost his own father to cancer; a tragedy that inspired him to co-found Calidi and make it his personal mission to bring to market a cure for difficult-to-treat cancers. Previously, Mr. Camaisa was the CEO and Chairman of Parallel6, Inc., a creator of a digital mobile software platform that engaged clinical trial participants and powered the enrollment, management, and retention of those participants on behalf of pharmaceutical organizations. Parallel6 was sold to PRA Health Sciences in 2017. Their clients included Sanofi, STSI/Genentech, Johnson & Johnson/Janssen, Abbott/Abbvie, PPD, PRA Health, Pfizer, Roche, and the NIH, among others. In 2005, Mr. Camaisa founded Anakam, Inc., a software security company that pioneered and patented SMS two-factor authentication, focused on healthcare, government, banking, and e-commerce, which safeguarded digital records and infotmation through a platform that delivered government-level multifactor authentication and security. Anakam sold a global license to the Veterans Administration (VA) to secure access to the VA’s primary patient portal called My HealtheVet. Other notable Anakam clients included the Center for Medicare and Medicaid, the Department of Homeland Security and several medical device companies including Boston Scientific and EntraHealth. Anakam was recognized by INC 500 as one of the fastest growing companies in the U.S. and was acquired by Equifax in 2010. Prior to Anakam, Mr. Camaisa founded High Technology Solutions (HTS) in the early 1990’s, a software systems integrator that he grew from two people to more than 500 employees and $50 million in revenue. Under his lead, HTS also developed and patented many technologies such as online car configuration, touchscreen kiosks, an online food delivery and ordering service. HTS was recognized as an INC 500 company three years in a row and was sold to Wireless Facilities, Inc. (now Kratos Defense) in 2004. Before entering business, Mr. Camaisa served eight years as a surface warfare officer in the United States Navy. He currently owns seven U.S. patents and has received many personal awards including the Deloitte FAST 50, the Governor’s Small Business of the Year Award and the Ernst and Young Regional Entrepreneur of the Year. He also received awards from the San Diego Asian Business Association, Tech America, and the U.S. Small Business Association, which honored him as Small Business Person of the Year. He is a graduate of both the United States Naval Academy and the prestigious Owners Management Program at Harvard Business School. Mr. Camaisa serves as a member of the YPO (Young Presidents Organization) San Diego Coastal Chapter. He also participated on several other volunteer boards including the United Way of San Diego, and Opportunity International (Micro-Enterprise Loans to the Poor).
Follow Allan Camaisa:
About Calidi Biotherapeutics: Calidi Biotherapeutics is a clinical-stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer.
Ignacio Martinez
Co-Founder, Chairman of the Board of Senda Biosciences
Ignacio Martinez is the Chairman of the Board and Co-Founder of Senda Biosciences. He joined Flagship Ventures in 2013 and focuses on sustainability and life sciences investments with a special interest in the agricultural sector. Ignacio holds a BS in Economics and Business Administration from Deusto University in Spain, and an International MBA from Instituto de Empresa in Spain, and WHU Otto Beisheim School of Management in Germany. Prior to joining Flagship, Ignacio was the Managing Director of Syngenta Ventures, where he was directly involved in investments in the agribusiness, biotechnology, and cleantech industries in Europe, North America, and Latin America. Syngenta Ventures is the venture capital arm of Syngenta International AG, the world’s largest agrochemical business with more than $13 billion in revenue. Ignacio has international board experience having served as Director in companies from seven different countries. He was also involved in corporate venture capital activities managing the relationship as a limited partner with Life Science Partners BioVentures, a $100 million Agribusiness fund, and the Gilde European Food and Agribusiness, a €90 million fund. Prior to Syngenta, Ignacio was the Chief Financial Officer of Progenika Group, where he was responsible for financial systems controls, transactions, and processes (GAAP/IFRS) reporting to the investors. He also oversaw spinoffs and M&A activity, participated in raising more than $50 million in funding, and actively participated in the expansion of the company to the US and Latin American markets. Before Progenika, Ignacio spent several years working for Najeti Ventures Fund investing in IT and biotech companies in Europe.
Follow Ignacio Martinez:
About Flagship Pioneering, Invaio Sciences, Senda Biosciences: Senda Biosciences is a therapeutics platform company leveraging unprecedented insights into the molecular connections between humans.
Brad Bostic
Founder, Chairman & CEO of hc1
Brad Bostic has been founding, leading, and investing in high-growth technology companies for the past 25 years. Frustrated by the prevalence of one-size-fits-all, trial and error patient care, Brad founded hc1 to save lives, save money, and eliminate wasteful practices with precision health insights that empower patients, providers, and health plans to make tailored care decisions. Today, the hc1 Platform analyzes billions of live data points across 20,000 provider locations to personalize care, improve outcomes, and eliminate waste for tens of millions of patients each year. By transforming lab and prescription data into personalized healthcare insights with cloud computing and machine learning, hc1 is the leader in critical insights, analytics, and solutions for precision health. Brad is among the top innovators in healthcare according to Becker’s Healthcare and was recognized as the 2020 Dynamic Leader of the Year by the Indiana Chamber of Commerce.
Follow Brad Bostic:
About hc1, Health Cloud Capital: Hc1 enables real-time lab stewardship and precision prescribing for health systems, laboratories and physicians.
Vinit Saxena
Founder,Chairman & CEO of Sepragen
Mr. Saxena is the Founder and Chief Executive Officer. His background includes over 25 years of senior management experience in marketing operations at biotech companies and suppliers such as Bio-Rad Laboratories and Bio-Response (now Baxter Healthcare). Mr. Saxena started the Process Chromatography business for Bio-Rad and is credited with setting up one of the first large scale antibody production facilities in the world. Mr. Saxena has an M.S. in Chemical Engineering from Syracuse University and an M.B.A. from the University of California, Berkeley. He holds 6 patents.
Follow Vinit Saxena:
About Sepragen: Sepragen provides break-through products and processes to the biotechnology and nutraceutical industries.
Jeffrey Port
Co-Founder & Chairman of Angiocrine Bioscience
Jeffrey Port is the Founder of Angiocrine Bioscience, Inc.
Follow Jeffrey Port:
About Angiocrine Bioscience, RF Surgical Systems, TMRW Life Sciences, Weill Cornell Medicine, Weill Cornell Medicine: Angiocrine Bioscience develops a cellular platform to amplify stem and progenitor cells in both human and mouse models.
Richard J Stephenson
Founder and Chairman of the Board of Cancer Treatment Centers of America
Follow Richard J Stephenson:
About Cancer Treatment Centers of America, Gateway for Cancer Research, International Capital & Management Company, Sheridan Capital Partners: CTCA has been helping patients win the fight against cancer using advanced technology and a personalized approach.
Eirini Schlosser
Chairman & CEO of Dyania Health
Follow Eirini Schlosser:
About Dyania Health, MedicusData.AI: Dyania Health develops a research platform for pharma companies and hospital systems.
Jerry Caulder
Chairman of Finistere Ventures
Jerry Caulder is Chairman at Finistere Ventures.
Follow Jerry Caulder:
About ZeaKal: Finistere Ventures is a venture capital firm that seeks investments in the agriculture sector.
Josef Parvizi
Chairman, Founder of Ceribell
Follow Josef Parvizi:
About Ceribell, Stanford University: Ceribell focuses on making electroencephalography (EEG) widely accessible, more efficient, and more cost-effective.
Timothy Walbert
Chairman, President & Chief Executive Officer of Horizon Pharma
Mr. Walbert has served as chairman of our board of directors since 2010 and our president and chief executive officer since June 2008. Mr. Walbert served as president, chief executive officer and director of IDM Pharma, Inc., a public biopharmaceutical company which was acquired by Takeda America Holdings, Inc., or Takeda, in June 2009. Prior to IDM, Mr. Walbert served as executive vice president, commercial operations at NeoPharm, Inc., a public biopharmaceutical company. From 2001 to 2005, Mr. Walbert served as divisional vice president and general manager, immunology, where he led the global development and launch of the multi-indication biologic HUMIRA, which is on track to exceed $10.0 billion in 2013 sales, and divisional vice president, global cardiovascular strategy at Abbott, now AbbVie. From 1998 to 2001, Mr. Walbert served as director, CELEBREX North America and arthritis team leader, Asia Pacific, Latin America and Canada at G.D. Searle & Company. From 1991 to 1998, Mr. Walbert also held sales and marketing roles with increasing responsibility at G.D. Searle, Merck & Co., Inc. and Wyeth. Mr. Walbert received his B.A. in business from Muhlenberg College, in Allentown, Pennsylvania. Mr. Walbert serves on the board of directors of XOMA Ltd. (NASDAQ: XOMA), Raptor Pharmaceutical Corp. (NASDAQ: RPTP), the Biotechnology Industry Organization (BIO), the Illinois Biotechnology Industry Organization (iBIO), ChicagoNEXT, a World Business Chicago (WBC) led council of technology leaders and the Greater Chicago Arthritis Foundation. Mr. Walbert was also recently appointed by Illinois Governor Pat Quinn to the Illinois Innovation Council.
Follow Timothy Walbert:
About Horizon Pharma, Horizon Therapeutics, Viela Bio: Horizon Therapeutics focuses on the development of prescription drugs for mild to moderate pain relief and arthritis.
Faheem Hasnain
Co-Founder & Executive Chairman of Gossamer Bio
Faheem Hasnain is the Chairman of the Board of directors at Ambit Biosciences Corporation. Faheem Hasnain has served as one of our directors since October 2010, and as the chairman of the board since November 2010. Faheem Hasnain is the president and chief executive officer of Receptos, Inc., a drug discovery and development company, a position he has held since December 2010.From December 2008 until its acquisition by Abbott Laboratories in April 2010, he was the president and chief executive officer and a director of Facet Biotech Corporation, a publicly-traded, biology-driven antibody company with a focus in oncology and multiple sclerosis. Faheem Hasnain was president, chief executive officer and a director of PDL BioPharma, Inc., a publicly-traded biotechnology company, from October 2008 until Facet Biotech was spun off from PDL BioPharma in December 2008. From October 2004 to September 2008, Faheem Hasnain served at Biogen Idec Inc., a biotechnology company specializing in neurological disorders, autoimmune disorders and cancer, most recently as executive vice president in charge of the oncology/rheumatology strategic business unit. Prior to Biogen Idec, Faheem Hasnain held roles with Bristol-Myers Squibb, where he was president of the oncology therapeutics network, and for 14 years at GlaxoSmithKline plc and its predecessor organizations. Faheem Hasnain has served on the board of directors of Somaxon Pharmaceuticals, Inc., a publicly-traded specialty pharmaceutical company, since September 2010. Faheem Hasnain received a B.H.K. and B.Ed. from the University of Windsor Ontario in Canada.
Follow Faheem Hasnain:
About Gossamer Bio, Vertex Ventures HC: Gossamer Bio is a biopharmaceutical company focused on the discovery and development of novel and differentiated therapeutic products.
John M. House
Co-Founder, Chairman, CEO & President of USMD
John M. House, M.D., a board-certified urologic surgeon, is the co-founder, chief executive officer and president of USMD Holdings. He is also the co-founder of Urology Associates of North Texas, one of the largest Urologic Surgery groups in North America. Dr. House received a B.S. in chemistry from the University of South Dakota and he received his Master’s Degree in chemical engineering at Texas Tech University. He then graduated from University of Oklahoma College of Medicine with a degree of Doctor of Medicine and subsequently completed his residency in urologic surgery at the University of Missouri in 1988. Dr. House is a Diplomat of the American Board of Urology and has served as a founding Board Member of the Large Urology Group Practice Association (LUPGA), a consortium of more than 50 large urology group practices.
Follow John M. House:
About USMD: USMD Holdings develops, operates and manages entities that deliver diagnostic, therapeutic and hospital-based health care to patients.
Jonathan Zhao
Co-Founder and Chairman of Hangzhou Just Biotherapeutics (Just China)
Asia strategy across small molecule, biologics and vaccine. He had also served as the interim head of Pfizer’s Bio-enhancement Development Unit during 2009-2010 in charge of the biosimilar and biobetter strategy development and business operation. Dr. Zhao received his B.S. in Pharmaceutical Sciences from Fudan University (Shanghai, China), PhD. magna cum laude in Analytical Chemistry from Ghent University (Ghent, Belgium), and MBA from Massachusetts Institute of Technology (Cambridge, USA). He has contributed more than 30 peer-reviewed publications and book chapters.
Follow Jonathan Zhao:
About Hangzhou Just Biotherapeutics (Just China), Transcenta: Hangzhou Just Biotherapeutics is a comprehensive high-tech design company.
Andre Watson
Founder, CEO & Chairman of Ligandal
Founder at Ligandal
Follow Andre Watson:
About Ligandal: Ligandal is creating cell-specific delivery systems for gene editing tools such as CRISPR using automation and peptide-based nanoparticles.
Dustin Shindo
Chairman and CEO of Pono Pharma
Dustin serves as the Chairman of the Board of Directors of Kai Medical. Dustin founded Hoku Corporation and served as its Chairman of the Board, President, and CEO from March 2001 to March 2010. While serving as Chairman of the Board, President, and CEO at Hoku, Dustin led the company to a successfully IPO on the NASDAQ Global Market. He also partnered with global customers including Sanyo, Nissan, Suntech Power, the US Navy, Solarfun, and others, with contracts totaling $2 Billion. Dustin has previously overseen successful ventures in both the software and manufacturing industries. Dustin has a B.A. in Accounting from the University of Washington and an M.B.A. from the Darden Graduate School of Business Administration at the University of Virginia.
Follow Dustin Shindo:
About Kai Medical, Pono Pharma: Pono Pharma develops and commercializes therapies for certain cancers and other diseases.
Ben Shapiro
Senior Partner, Chairman of PureTech Health
Dr. Shapiro is a Senior Partner and Chairman of the Board at PureTech Ventures. He was previously Executive Vice President, Worldwide Licensing and External Research for Merck. He joined Merck Research Laboratories in 1990 as Executive Vice President, Basic Research. In this position he was responsible for all basic and preclinical research activities at Merck worldwide. Dr. Shapiro led the research program that resulted in FDA registration of approximately 25 drugs and vaccines. From 1999-2003 Shapiro oversaw all in-licensing activities for Merck. Previously, he was Professor and Chairman of the Department of Biochemistry at the University of Washington. He is the author of over 120 papers on the molecular regulation of cellular behavior and the biochemical events that integrate the cascade of cellular activations at fertilization. He has served on many institutional advisory boards and scientific review panels, and is currently a member of the board of various life science companies, including VBL, Celera, Momenta, Elixir, Satori, and Ikaria. He also sits on the boards of the Drugs for Neglected Disease Initiative and the Mind and Life Institute. Dr. Shapiro received his MD from Jefferson Medical College.
Follow Ben Shapiro:
About PureTech Health: PureTech Health is a bio pharma company and pushes the boundaries of medicine and changing and converging healthcare ecosystem.
David Perry
Chairman and Co-founder of Better Therapeutics
David is President, CEO, and Director of Indigo. He is a serial entrepreneur who has founded and built three innovative companies in the last 18 years, leading the last two through successful IPOs and to multi-billion dollar market capitalizations, and raising over $750 million, while generating significant returns for investors. David was most recently CEO and Co-Founder of Anacor Pharmaceuticals (NASDAQ: ANAC), a biopharmaceutical company discovering and developing novel small-molecule therapeutics to treat infectious and inflammatory diseases. David previously co-founded and served as CEO of Chemdex (NASDAQ: CMDX), later creating its parent company Ventro Corporation (NASDAQ: VNTR), a business-to-business marketplace focused on the life sciences industry. At its peak, Ventro was valued at $11 billion and was later sold to Nexprise. David is Founder and Chairman of the San Francisco-based digital health startup, Farewell, and a Director of the human microbiome company, Epiva. In 2000, David was named Entrepreneur of the Year in Northern California by Ernst and Young. He holds an M.B.A. from Harvard Business School and a B.S. in chemical engineering from the University of Tulsa. He also attended the United States Air Force Academy, where he was a National Merit Scholar. David serves as a Director of the not-for-profit Infectious Disease Research Institute. In 1995, Mr. Perry co-founded Virogen, a biotech company based in Boston. Mr. Perry has a B.S. from the University of Tulsa and an M.B.A. from Harvard Business School.
Follow David Perry:
About Better Therapeutics: Better develops prescription software for treating cardiometabolic diseases.
Gregory C. Critchfield
Chairman, President and CEO of Sera Prognostics
Dr. Gregory Critchfield is CEO of Sera Prognostics, a private biotechnology company developing novel diagnostic tests for the early prediction of preterm birth and other pregnancy complications. He currently serves as an independent director of Saladax Biomedical, Metamark Genetics and Nodality. Dr. Critchfield is also past President of Myriad Genetic Laboratories, Inc., where he successfully established the company’s medical, scientific, and commercial capabilities beginning in 1998 until he retired in March 2010. During this time, Dr. Critchfield built Myriad Genetic Laboratories into one of the world’s leading molecular diagnostics companies, launching seven novel diagnostics products across multiple technology platforms and growing annual revenues from $2.2 million to $326.5 million. In the spin-out of Quest Diagnostics, Inc. from Corning Clinical Laboratories, Dr. Critchfield was responsible for innovation and medicine, serving as Quest’s Chief Medical and Science Officer. From 2007 to 2009, Dr. Critchfield served as an independent Director of BioTrove, a venture-backed molecular biological tools company. In that position he collaborated with Albert A. Luderer, Ph.D., CEO of Indi, who was then BioTrove’s CEO. They worked together at BioTrove until that company was successfully acquired by Life Technologies in December 2009. In 2007, Dr. Critchfield chaired the Utah Governor’s State Advisory Council on Science and Technology. He served on the Board of the American Clinical Laboratory Association (ACLA). Earlier in his career Dr. Critchfield worked as a practicing clinical pathologist with Intermountain Healthcare for nine years. Previously, he served as a reviewer and study section chair for the NIH for more than 15 years, working in biomedical computing programs for SBIR, STTR and R01 programs. Dr. Critchfield’s research has focused on building quantitative models in many areas of laboratory medicine including anticoagulation control, method standardization, mass spectrometric identification of drugs, predictive value modeling, quantitative health policy analysis and clinical genetics. He has served on the faculty of three medical schools: University of Minnesota, Wayne State University and Duke University. Dr. Critchfield received a Bachelor’s Degree in Microbiology with a minor in Chemistry from Brigham Young University in 1976, an M.D. from the University of Utah in 1980, and a master’s degree in Biophysical Sciences at the University of Minnesota in 1985. He also completed fellowships in Clinical Chemistry and in Health Information Sciences sponsored by the National Library of Medicine and is board certified in Clinical Pathology.
Follow Gregory C. Critchfield:
About Duke University, Epic Sciences, Sera Prognostics, Wayne State University: Sera Prognostics develops blood tests that are predictive of preterm birth, preeclampsia, and other pregnancy complications.
Mitchel Berger
Professor and Chairman, Department of Neurological Surgery of UCSF health
Dr. Berger’s main clinical interests are the treatment of brain tumors in adults and children and of epilepsy related to brain tumors. He has extensive expertise in intraoperative mapping of the brain to identify the sites of motor, sensory, and language function and thereby avoid their involvement or injury during surgery. Dr. Berger is Director of the Adult Hydrocephalus and Shunt Program, and he also practices in the Neuro-Oncology Program and the Radiosurgery Program.
Follow Mitchel Berger:
About UCSF health: UCSF health offers healthcare services in the areas of cancer, heart disorders, neurological disorders, organ transplants, and more.
Mark Gurney
Chairman / CEO of Tetra Discovery
Mark Gurney founded Tetra Discovery Partners as a drug development company in 2011 to develop meaningful medications for large unmet needs including Alzheimer’s disease. He has held positions in academia and within the pharma industry. Dr. Gurney was named one of two leading inventors in the field of Alzheimer’s Disease therapeutics for his discovery of the beta-secretase, a key enzyme in the amyloid pathway that releases the A-beta peptide from the amyloid protein precursor. Dr. Gurney’s resume with biotech companies includes work in drug discovery and development as Senior Vice President at deCODE genetics, Inc.; Director Genomics, Pharmacia Corporation; Associate Professor, Northwestern University Feinberg School of Medicine; and Assistant Professor, University of Chicago Medical School. In addition to his work on Alzheimer’s disease, Dr. Gurney developed the SOD1-G93A transgenic mouse model of ALS. Dr. Gurney has authored 117 peer reviewed papers that have been cited over 18,000 times and holds 36 issued patents. He earned a PhD in neuroscience from the California Institute of Technology and an MBA from the Kellogg Graduate School of Management at Northwestern University.
Follow Mark Gurney:
About Tetra Discovery, Tetra Therapeutics: Tetra Discovery provides consulting services and research on drug discovery for diseases affecting the central nervous system.
Parker H. Petit
Chairman of MiMedx Group
Pete Petit joined MiMedx® Group, Inc. in February 2009 as the Company’s Chairman and Chief Executive Officer. A visionary healthcare executive, he has a history of developing companies from their emerging stages and leading them to maturity and significant stature in their respective markets. In 1970, Mr. Petit founded Healthdyne, an international healthcare company that manufactured high technology healthcare devices, provided healthcare information systems and technology, and provided healthcare services and disease management. The Healthdyne related companies grew to annual revenues in excess of $1 billion. In order to increase shareholder values, Healthdyne was split into several publicly traded companies through public offerings and spinouts to shareholders in 1995. At that point, he relinquished the CEO role and remained Chairman of the Board of all the companies. Subsequently, the home infusion therapy subsidiary was sold to W. R. Grace Corporation. In 1995, Healthdyne Maternity Management was merged with Tokos Medical to form Matria Healthcare. In 1997, Healthdyne Technologies was merged with Respironics. He resumed the duties of President and CEO of Matria Healthcare in 2000. In 2001, Healthcare.com, which was formerly Healthdyne Information Enterprises, merged with XCare.net Corporation to form Quovadx. Through his vision and leadership, Matria Healthcare transitioned into the industry’s only fully integrated health, productivity and disease management care continuum providing employer and health plan clients access to wellness programs, nurse triage services, decision support programs, disease management programs for chronic diseases, case management programs for acute and catastrophic conditions and unparalleled health data integration and informatics. Matria Healthcare was sold to Inverness Medical Innovations in May of 2008 in a transaction valued at over $1.2 billion. Pete Petit served on the Board of Directors of Atlantic Southeast Airlines for 16 years until it was acquired by Delta Airlines, and Norrell Corporation, which was acquired by Spherion Corporation. He currently serves on the Board of Trustees of the National Health Museum and is a member of the Board of Directors of Intelligent Systems Corporation. He is a member of the Board of Directors of the Georgia Research Alliance, which is chartered by the state of Georgia to promote high technology and scientific development in the state, and he is a 1994 inductee into the Technology Hall of Fame of Georgia. Mr. Petit received his Bachelor’s degree in Mechanical Engineering and Master of Science degree in Engineering Mechanics from Georgia Tech. He received his MBA degree in Finance from Georgia State University in 1973.
Follow Parker H. Petit:
About MiMedx Group: MiMedx Group provides regenerative biologics utilizing human placental tissue allografts with patent-protected processes.
Charlie Stiefel
Chairman of the Board of Directors of Brickell Biotech
Prior to joining Brickell, Charles was chairman and CEO of Stiefel Laboratories, Inc. Founded in 1847, Stiefel Laboratories was a family-owned company for more than 160 years until it was sold to GlaxoSmithKline in 2009. At the time, Stiefel Laboratories was the world’s largest privately held pharmaceutical company specializing in dermatological products, with nearly 4,000 employees in more than 30 countries and products distributed in more than 100 countries. Charles first joined the company as general counsel in 1982 and was subsequently named executive vice president and then president. In 2003 Charles was awarded a Lifetime Achievement Award by the South Florida Dermatology Foundation, and in 2006 he was named Ernst & Young’s Entrepreneur of the Year in Health Sciences for the state of Florida. Born in Catskill, New York, Charles holds an undergraduate degree from Yale University and a JD degree from Albany Law
Follow Charlie Stiefel:
About : Brickell Biotech is focused on the acquisition, development, and commercialization of drug therapies for the treatment of skin diseases.
Kenneth M. Corroon
Co-Founder, CEO & Chairman of Aponia Laboratories
Kenneth M. Corroon serves as the Chief Executive Officer at Aponia Laboratories Inc. Kenneth Corroon serves as Director of Aponia Laboratories Inc. He serves as Director of Harmony Pharmacy & Health Center, Inc. He served as Founder, Chief Executive Officer, and President at Homeostasis Laboratories, Inc. Kenneth Corroon was the Co-Founder at Harmony Health & Beauty, Inc. in 2005 and served as its Chief Executive Officer. Kenneth Corroon served as a Vice President of Kidder, Peabody & Co. He served as Chairman and Director of Homeostasis Laboratories, Inc. He served as Chairman of Kidder, Peabody & Co. He also worked for Morgan Stanley in New York as an investment banker in its Financial Sponsors Group focusing on the retail industry and spent four years at UBS Investment Bank as a Director.
Follow Kenneth M. Corroon:
About Aponia Laboratories: Aponia Laboratories is a pharmaceutical company producing a series of clinically proven prescription pain relief products.
Paul R Edick
Chairman & CEO of Xeris Pharmaceuticals
Mr. Edick joined Xeris Pharmaceuticals as Chairman and Chief Executive Officer in January 2017. Prior to his time at Xeris, Mr. Edick was Founding Partner of 3G Advisors, a consultancy to the pharmaceutical, healthcare, and healthcare investor communities. From 2010 to 2014, Mr. Edick was the Chief Executive Officer of Durata Therapeutics (Nasdaq: DRTX), a biopharmaceutical company addressing the growing need for new antibiotics to treat infectious diseases. Durata was acquired by Actavis plc, now Allergan plc, in November 2014. Prior to Durata, Mr. Edick was Chief Executive Officer of Ganic Pharmaceuticals, a Warburg Pincus investment search vehicle, from 2008 to 2010. Before Ganic, Mr. Edick was Chief Executive Officer of MedPointe Healthcare, Inc., a US-based specialty pharmaceutical company, a position he assumed in 2006, having been President of Pharmaceutical Operations since 2002. Mr. Edick led the growth of the business and the development of a clinical stage portfolio, and the company was subsequently sold to Meda AB of Sweden in 2007. Mr. Edick also has extensive industry experience with leading consumer, pharmaceutical and healthcare organizations, including Pharmacia as Group Vice President and President, Asia Pacific & Latin America Operations at Pharmacia; and Searle Pharmaceuticals as President of Asia Pacific, Canada & Latin America Operations, VP, Canada & Latin America Operations. He also has experience leading the US managed care organization, US marketing organization and Global Pain & Inflammation Business, including the commercialization and launch planning for Celebrex®. In addition, Mr. Edick has also held sales, marketing, advertising, and advisory positions in Procter & Gamble, Ortho Pharmaceuticals, and The Hamilton Group.
Follow Paul R Edick:
About Xeris Pharmaceuticals: Xeris Pharmaceuticals is a pharmaceutical company that develops therapies for patients in endocrinology, neurology, and gastroenterology.
Jeffrey D. Wager
Co-Founder, Chairman & CEO of EnBiotix
Follow Jeffrey D. Wager:
About EnBiotix, Proterris: EnBiotix advances front-line labeled products for chronic, recurrent, and life-threatening pulmonary infections.
Gary Stroy
Chairman of Xip
Follow Gary Stroy:
About Xip: Xip produces disposable blood analyzers that wirelessly upload lab-quality clinical measurements in minutes.
Matthew De Silva
Founder & Executive Chairman of Notable Labs
Follow Matthew De Silva:
About Bank of America, Notable Labs: Notable Labs provides personalized drug combination testing service for cancer patients.
Tim Almond
Chairman & Founder of Heartland Industries
“I think like a hacker, because only then can you spot flaws in perfection.” I enjoy building new technology to solve problems.
Follow Tim Almond:
About Heartland Industries: Heartland is a biotech company that engineers hemp fibers as additives for plastics.
Jeffrey Binder
Chairman and Chief Executive Officer of CLS Holdings USA
Prior to founding CLS, Mr. Binder served as founder, Chairman and President of Power 3 Network, Inc., a company that develops websites and back offices for home-based businesses. Mr. Binder has invested in and mentored several start-up and mid-stage companies, through his private holding company, JeMJ Financial Services, Inc., which he formed in 1988. Mr. Binder received his Juris Doctorate from the National Law Center, George Washington University, in 1971, where he received the honor of membership in the Order of the Coif. He also served as a legislative assistant to Adlai Stevenson II, a United States Senator for Illinois, and practiced Law at Sonnenschein Nath & Rosenthal, LLP, Chicago, Illinois for five years.
Follow Jeffrey Binder:
About CLS Holdings USA: CLS focuses on the extraction and conversion of cannabinoids in the United States.
Howard Leonhardt
Executive Chairman & CEO of BioLeonhardt
Howard Leonhardt is the CEO at Leonhardt Ventures.
Follow Howard Leonhardt:
About BioLeonhardt, Cal-X Crowdfund Connect, Cal-X Stars Business Accelerator, Christiana Leucas Foundation, Food Trikes & Scooters, Heartscore, InStim, Kindheart Lionheart Adventures, KindHeartLionHeartTV, Leonhardt Ventures, Leonhardt Vineyards, Leonhardt Vineyards, Lucilles American Cafe, Radio Veronica USA, Second Heart Assist, Inc., Startup California, Stem Cell Bra, VascuStim, Wine Country Baseball: BioLeonhardt – Has developed a programmable implantable stem cell pump and electrical stimulator.
Jacob Goldfield
Chairman of CombinatoRx
Jacob is a successful option trader who retired as a senior partner of Goldman Sachs. He was later the CIO of Soros Fund Management and Quantum before starting his own firm. He has invested and served as a board member for several private biotech companies in the past including serving as Chairman of the Board of CombinatorX Inc.
Follow Jacob Goldfield:
About : CombinatoRx is a biotech company that develops medicines from synergistic combinations of approved drugs.
Vivek Ramaswamy
Founder & Executive Chairman of Roivant Sciences
Vivek Ramaswamy is Founder and Chief Executive Officer of Roivant Sciences. Roivant advances the development and delivery of important medicines in disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal needs. Roivant also builds technology-focused subsidiaries focused on improving the process of developing and commercializing medicines. Roivant and its family of companies employ over 900 professionals today. Mr. Ramaswamy graduated summa cum laude in Biology from Harvard University in 2007 and began his career as a successful biotech investor where he oversaw investment in numerous companies, including those that helped develop curative treatment regimens for hepatitis C virus. He continued to work as an investor while earning his law degree from Yale Law School, where he was a Paul & Daisy Soros Fellow.
Follow Vivek Ramaswamy:
About Roivant Sciences: Roivant Sciences is a biopharmaceutical company focused on the development of medicines and healthcare technologies to patients.
Kamran Siminou
Executive Chairman & Founder of NeurOptics
Kamran Siminou experience spans 20 years in Research and Development, Marketing and Business Development for leading healthcare companies such as General Electric and Baxter International. Kamran is named as an Inventor in over 20 patents as it relates to infrared pupillometry and its application in neurocritical care and ophthalmology. Kamran holds a Bachelor of Science in Electrical Engineering from University of Central Florida, an MBA from University of California-Irvine, and the Stanford Executive Program (SEP) from Stanford University.
Follow Kamran Siminou:
About NeurOptics: NeurOptics manufactures devices that gather and process information from the human eye to support medical decision-making and researches.
David Hysong
Founder, Patient & Chairman of SHEPHERD Therapeutics
SHEPHERD is a biotechnology company that develops novel therapeutic candidates for a portfolio of rare cancers. SHEPHERD is also a development partner to other biopharma companies looking to develop their assets in rare cancers. Via SHEPHERD’s in-house capabilities and A.I. platform, DELVE, SHEPHERD can help match any drug with the rare cancers in which it will be most effective.
Follow David Hysong:
About Forbes, SHEPHERD Therapeutics, SHEPHERD Therapeutics, The Aspen Institute: SHEPHERD Therapeutics specializes in finding cure to rare cancers.
Pep Gubau
Executive Chairman, CTO & Co-Founder of Aizon
Pep is an IT entrepreneur and has been working in IT for the last 25 years, being pioneer in Linux adoption in the 90s, cloud in the 2000s and big data in the last years. Although having a theoretical economics and maths profile, his early career was as a software developer for the chemical industry. He later was CTO & COO of an IT consulting firm, leading a team of more than 200 engineers until 2003 when Pep created his first IT company with a clear core principle: customer centric focus. Two more followed. In 2013 Pep started thinking on the next thing to work on. bigfinite is the result of this initial spark that immediately caught fire in Pere and Toni. Pep is Economist (University of Barcelona) with an engineering background.
Follow Pep Gubau:
About Aizon: Aizon is a cloud-based SaaS platform that helps optimize industrial processes in biotech and pharma.
Mike Doodson
Executive Chairman and Co-founder of G2B Pharma
Follow Mike Doodson:
About G2B Pharma: G2B Pharma is a biotechnology company focused on the reformulation of off-patent drugs.
Marc de Garidel
Chairman of Ipsen
Born in 1958, Marc de Garidel is a graduate of École Spéciale des Travaux Publics (a leading French civil engineering school), and holds a Master’s degree from the Thunderbird School of Global Management (Arizona, US) and an Executive MBA from Harvard Business School (Massachusetts, US). He began his career with pharmaceutical company Eli Lilly in 1983, where he held various roles, mainly finance-related, in France, the US and Germany. In 1995, Marc de Garidel joined Amgen, an American biotech company, where he held positions of increasing responsibility in finance. In 1998, he was appointed Corporate Controller of Amgen, based in the US. In 2000, he was appointed General Manager of Amgen’s French affiliate and progressively oversaw an increasing number of countries before heading the Southern region of Amgen International, the group’s most important region in terms of sales. Between 2010 and 2012, Marc de Garidel was Chairman of the European Biopharmaceutical Enterprises association. Marc de Garidel has been Chairman and spokesperson of the G5, an association of eight leading French healthcare companies, since January 2011. He has been Vice President of France’s Healthcare Industries and Technologies Strategic Committee since July 2011. Marc de Garidel is a board member of the EFPIA (European Federation of Pharmaceutical Industries and Associations) and of Inserm-Transfert. He is non-executive chairman of Promethera Biosciences’ board of directors in Belgium. Marc de Garidel is a knight of France’s National Order of the Legion of Honor and a board member of the Society of Members of the Legion of Honor. He teaches at the Master’s Programs of French business schools, ESSEC and ESCP Europe.
Follow Marc de Garidel:
About AZTherapies: Ipsen develops and markets medications used in oncology, neuroscience and rare diseases along with consumer healthcare products.
Dimitri Krainc
Scientific Founder, Chairman of the Scientific Advisory Board of Lysosomal Therapeutics
Dimitri is Aaron Montgomery Ward Professor of Neurology, Chairman of the Ruth and Ken Davee Department of Neurology at the Feinberg School of Medicine and Northwestern Memorial Hospital and Director of Center for Rare Neurological Diseases at Feinberg. Previously, he spent 20 years at Harvard Medical School completing his research training followed by a neurology residency and fellowship in movement disorders at Massachusetts General Hospital (MGH) and Brigham and Women’s Hospital. He then served on the clinical and research faculty in the Department of Neurology at MGH and Harvard Medical School.
Follow Dimitri Krainc:
About Lysosomal Therapeutics: Lysosomal Therapeutics deliver cures for neurodegenerative diseases.
Daniel Zurr
CEO, Founder and Chairman of the Board of Quark Pharmaceuticals
Daniel Zurr Ph.D., CEO, Founder and Director, former President of Plantex Ikapharm (currently part of the Teva Group). Dr. Daniel Zurr founded Quark in 1993 and is currently CEO of the Company. Dr. Zurr also currently serves as a Director of QBI. Dr. Zurr has vast experience in senior research and business management in the chemical and pharmaceutical industries. Prior to establishing QBI, Dr. Zurr was the CEO of Plantex-Ikapharm, then the second largest pharmaceutical company in Israel with more than 300 employees and marketing offices in the United States, Europe and Japan, focused in the field of bulk active ingredients and finished dosage pharmaceuticals. During Dr. Zurr’s tenure, Plantex Ikapharm, now part of the Teva group of companies, became the first Israeli company ever to be inspected and approved by the FDA. In the early eighties, Dr. Zurr served as the Director of Licensing at G.D. Searle in Skokie, Illinois, where he was responsible for the major collaborative agreement between G.D. Searle and Meiji Seika Kaisha (Tokyo), involving the licensing of several drugs and recombinant DNA technology transfer. Dr. Zurr was also responsible for numerous other agreements, including those with Bayer AG (Leverkusen), Ono Pharmaceutical (Osaka) and May and Baker (London).
Follow Daniel Zurr:
About Kunshan RiboQuark Pharmaceutical Technology, Quark Pharmaceuticals: Quark Pharmaceuticals is a clinical-stage pharmaceutical company engaged in the discovery and development of novel RNAi-based therapeutics.
Daniel M. Bradbury
Chairman of the Board and Chief Executive Officer of Equillium
Daniel M. Bradbury is Director at Liquid Grids.
Follow Daniel M. Bradbury:
About Alume Biosciences, BioBrit, Biocon, Equillium, Equillium, Intercept Pharmaceuticals, IQHQ, Keck Graduate Institute, ProSciento, Sensulin, Synedgen: Equillium is a biotechnology company that develops products for autoimmune and inflammatory disorders with an unmet medical need.
Vicente Sáez González
Vice Chairman of Ixaka
Vicente is an experienced healthcare investor with over 20-years’ experience in numerous companies in Spain and in other European countries. These include Vidia Health, S.A., Group Axys Biosciences S.A, Estadista, S.A. and Iris Development S.A. Vicente is a co-founder and principal shareholder of Rexgenero and has significant experience of companies with partnerships with the public sector in Spain.
Follow Vicente Sáez González:
About : Ixaka is a private cell and gene therapy company with a focus on the natural power of the body to cure disease.
Greg Schmergel
Executive Chairman of Yuva Biosciences
Before Nantero, Greg Schmergel was Senior Vice President, Corporate Strategy for About, Inc., at the time the 5th largest Web property. Previously he was President and CEO of ExpertCentral.com, Inc. Greg founded ExpertCentral.com in 1998 to provide consumers and small businesses with access to thousands of experts to use as an online resource for important questions on a wide variety of topics. Before that, he was a Case Team Leader for Bain & Company. His earlier experience includes senior positions at TowerGroup, which he helped start, and the Ernst & Young Center for Information Technology & Strategy. Reuters acquired TowerGroup in November 1999 and About, Inc. acquired ExpertCentral.com. Greg stays active in supporting entrepreneurship at Harvard, MIT, and throughout Boston, including being a guest speaker at entrepreneurial classes and groups, a past judge in MIT business plan competitions, a Board member on the Mass Technology Leadership Council, and a judge in the MassChallenge entrepreneurship program. He holds an AB magna cum laude from Harvard University and an MBA from the Harvard Graduate School of Business Administration. Greg was selected as the 2006 Ernst & Young Entrepreneur of the Year Award winner in New England, in the emerging technology category. The Ernst & Young Entrepreneur Of The Year awards program honors entrepreneurs who have demonstrated excellence and extraordinary success in such areas as innovation, financial performance, and personal commitment to their businesses and communities.
Follow Greg Schmergel:
About Rubicon Venture Capital, Yuva Biosciences: Using cutting edge mitochondrial science to develop cosmeceuticals and pharmaceuticals.
Kevin Conroy
Chairman & CEO of Exact Sciences
Kevin T. Conroy is President, Chief Executive Officer and Chairman of the Board of Exact Sciences. In 2004, he joined Third Wave Technology where he was the company’s General Counsel. From 2005 to July of 2008, Mr. Conroy served as Third Wave’s President and Chief Executive Officer until their acquisition by Hologic. Prior to joining Third Wave, Conroy served as Intellectual Property counsel at GE Healthcare. Before joining GE Healthcare, Conroy was Chief Operating Officer of two early stage, venture-backed technology companies in Northern California. Prior to those positions, he was an Intellectual Property litigator at two Chicago law firms: McDermott Will & Emery; and Pattishall, McAuliffe, Newbury, Hilliard and Geraldson, where he was a partner. He earned a Bachelor of Science degree in electrical engineering from Michigan State University, as well as a Law degree from the University of Michigan Law School.
Follow Kevin Conroy:
About Exact Sciences, SportsEdTV: Exact Sciences is the developer and manufacturer of Cologuard, a non-invasive screening test for the early detection of colorectal cancer.
Michael Demurjian
Manager, Founder, Chairman & CEO of Aspargo Laboratories
Michael Demurjian is a Manager, Founder, Chairman & CEO of Aspargo Laboratories. He is a successful biotech entrepreneur who has founded and successfully built several technology companies; co-founder of Tyme Inc. (Nasdaq: TYME) a clinical-stage biotechnology company developing metabolic-based cancer therapeutics.
Follow Michael Demurjian:
About Aspargo Laboratories: Aspargo Laboratories commercialize the rights of an oral suspension spray formulation of erectile dysfunction medication Sildenafil citrate.
William Rohn
Chairman of the Board of Directors of Pfenex
William Rohn, age 71, has served as a member of our Board of Directors since March 2012. William served as Chief Operating Officer of Biogen Idec, the successor company to IDEC Pharmaceuticals, a biotechnology company, from 2003 until 2005. From 1998 until 2003, William was President and Chief Operating Officer of IDEC Pharmaceuticals, a biotechnology company. William joined IDEC in 1993 as Senior Vice President, Commercial and Corporate Development and was appointed Senior Vice President, Commercial Operations in 1996. From 1985 until 1993, William was employed by Adria Laboratories, a pharmaceutical company that has since been acquired by Pfizer Inc., most recently as Senior Vice President of Sales and Marketing. Before moving to the fledgling biotech industry in its early days, William spent approximately 25 years in the pharmaceutical sector in a variety of commercial operating roles of increasing responsibility with such companies as Abbott Laboratories, Bristol-Myers Squibb Co., and Adria Laboratories (now part of Pfizer). He is Chairman of the Board at Pfenex Inc., a developer of biosimilar protein pharmaceuticals. William’s knowledge of our industry and his prior and current experience as a senior officer and director of other healthcare companies contributed to our conclusion that he should serve as a director.
Follow William Rohn:
About : Pfenex develops biosimilar therapeutics and novel vaccines for the treatment and prevention of critical human health issues.
Harrison Dillon
Chairman & Co-founder of Phylagen
Harrison Dillon is the Chairman and Co-Founder of Phylagen.
Follow Harrison Dillon:
About Phylagen: Phylagen is digitizing the global microbiome to create a more transparent world
William H. Danforth
Chairman of Donald Danforth Plant Science Center
Dr. William H. Danforth is Founding Chairman of the Board of Trustees of the Donald Danforth Plant Science Center, Chancellor Emeritus of Washington University and Chair of the BioStL Coalition. Born in St. Louis, Missouri, on April l0, l926, he received his B.A. from Princeton University and his M.D. from Harvard Medical School in l95l. After completing his internship in medicine at Barnes Hospital, St. Louis, Missouri, he served in the United States Navy from l952-54. He returned to St. Louis to continue his medical training at Barnes Hospital and at St. Louis Children’s Hospital. Dr. Danforth joined the Washington University Medical School faculty in l957. In l967, he was appointed professor of internal medicine, which is his present faculty rank at the University. From l965-7l, Dr. Danforth served as Vice Chancellor for Medical Affairs and as president of the Washington University Medical Center. Dr. Danforth became Washington University’s thirteenth Chancellor July l, l97l and served until his retirement June 30, l995. During this time the University recruited many eminent plant scientists. He also served as Chairman of the Board of Trustees of Washington University from July l, l995 to June 30, 1999. Dr. Danforth is a member of the Institute of Medicine and served on the Council l977-79. Dr. Danforth was appointed to chair the Research, Education and Economics Task Force for the USDA by Agriculture Secretary Ann M. Veneman in 2003. The Task Force reported in 2004. That report led to legislation by the Congress that established the National Institute for Food and Agriculture, which began with great hopes for support for high quality agricultural research. He is a trustee of the American Youth Foundation and a former trustee of the Danforth Foundation. He co-chaired the Board of Directors of Barnes-Jewish Hospital and served on the Boards of Directors of Ralston Purina Company, McDonnell-Douglas Corporation, BJC Health System and Energizer Holdings, Inc.
Follow William H. Danforth:
About Donald Danforth Plant Science Center: Donald Danforth Plant Science Center is a non-profit research institute developing plant science solutions to improve human conditions.
Rowland Hanson
Chairman of UVLrx Therapeutics
Former Vice President of Worldwide Marketing for Neutrogena Corp. Recruited by Bill Gates at Microsoft where he was Vice President of Corporate Communications and created and executed branding strategy for “Windows,” which he named.
Follow Rowland Hanson:
About eSurface, UVLrx Therapeutics: UVLrx Therapeutics is a biotechnology company that specializes in the fields of medical, healthcare, and therapeutics.
Mark A. Emalfarb
Founder, Chairman & CEO of Dyadic International
Mark A. Emalfarb is the founder of Dyadic. He has been a member of Dyadic’s board of directors since October 2004, served as its Chairman from October 2004 until April 2007 and from June 2008 until January 2015 and has served as President and Chief Executive Officer from October 2004 until April 2007 and from June 2008 until the present. Since founding Dyadic in 1979, Mr. Emalfarb has successfully led and managed the evolution of Dyadic from its origins as a pioneer and leader in providing ingredients used in the stone-washing of blue jeans to the discovery, development, manufacturing and commercialization of specialty enzymes used in various industrial applications and the development of an integrated technology platform based on Dyadic’s patented and proprietary C1 fungal microorganism. Mr. Emalfarb is an inventor of over 25 U.S. and foreign biotechnology patents and patent applications resulting from discoveries related to the Company’s patented and proprietary C1 fungus, and has been the architect behind its formation of several strategic research and development, manufacturing and marketing relationships with U.S. and international partners. Mr. Emalfarb earned his B.A. degree from the University of Iowa in 1977.
Follow Mark A. Emalfarb:
About Dyadic International: Dyadic International is a biotechnology company, developing and manufacturing bio-based chemicals.
